TrialCancer science2026

Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial.

Chunlin Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.